Bevacizumab decreases vestibular schwannomas growth rate in children and teenagers with neurofibromatosis type 2

Journal of Neuro-Oncology

Volumn 124, Issue 2, 2015, Pages 229-236

  Hochart, Audrey ^a   Gaillard, Vianney ^b   Baroncini, Marc ^b   André, Nicolas ^c,d   Vannier, Jean Pierre ^e   Vinchon, Matthieu ^b   Dubrulle, Frederique ^b   Lejeune, Jean Paul ^b   Vincent, Christophe ^b   Nève, Véronique ^b   Sudour Bonnange, Héléne ^a   Bonne, Nicolas Xavier ^b   Leblond, Pierre ^a  

^a CENTRE OSCAR LAMBRET   (France)

^b LILLE UNIVERSITY HOSPITAL   (France)

^c TIMONE HOSPITAL   (France)

^d AIX MARSEILLE UNIVERSITY   (France)

^e HÔPITAL CHARLES NICOLLE   (France)

Author keywords

Bevacizumab; Neurofibromatosis type 2; Pediatric; Vestibular schwannoma

Indexed keywords

BEVACIZUMAB; ANGIOGENESIS INHIBITOR;

ACOUSTIC NEURINOMA; ADOLESCENT; ADULT; AGE DISTRIBUTION; ARTICLE; AUDIOMETRY; CANCER INHIBITION; CHILD; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EPISTAXIS; FAINTNESS; FEMALE; FOLLOW UP; HEARING; HUMAN; HYPERTENSION; MALE; METRORRHAGIA; NEUROFIBROMATOSIS TYPE 2; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEITIS; OSTEOMYELITIS; PROTEINURIA; RETROSPECTIVE STUDY; SCHOOL CHILD; SCORING SYSTEM; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR VOLUME; WORD RECOGNITION; WOUND HEALING IMPAIRMENT; YOUNG ADULT; DISEASE COURSE; FRANCE; NEUROMA, ACOUSTIC; PATHOLOGY; PATHOPHYSIOLOGY; TREATMENT OUTCOME;

ADOLESCENT; ANGIOGENESIS INHIBITORS; AUDIOMETRY; BEVACIZUMAB; CHILD; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; FRANCE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; NEUROFIBROMATOSIS 2; NEUROMA, ACOUSTIC; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; TUMOR BURDEN; YOUNG ADULT;

EID: 84942500393     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-015-1828-8     Document Type: Article

References (23)

1. Evans DGR, Moran A, King A et al (2005) Incidence of vestibular schwannoma and neurofibromatosis 2 in the North West of England over a 10-year period: higher incidence than previously thought. Otol Neurotol 26(1):93–97
2. Baser ME, Friedman JM, Aeschliman D et al (2002) Predictors of the risk of mortality in neurofibromatosis 2. Am J Hum Genet 71(4):715–723
3. Mathieu D, Kondziolka D, Flickinger JC et al (2007) Stereotactic radiosurgery for vestibular schwannomas in patients with neurofibromatosis type 2: an analysis of tumor control, complications, and hearing preservation rates. Neurosurgery 60(3):460–470
4. Plotkin SR, Stemmer-Rachamimov AO, Barker FG et al (2009) Hearing improvement after bevacizumab in patients with neurofibromatosis type 2. N Engl J Med 361(4):358–367
5. Uesaka T, Shono T, Suzuki SO et al (2007) Expression of VEGF and its receptor genes in intracranial schwannomas. J Neurooncol 83(3):259–266
6. Cayé-Thomasen P, Werther K, Nalla A et al (2005) VEGF and VEGF receptor-1 concentration in vestibular schwannoma homogenates correlates to tumor growth rate. Otol Neurotol 26(1):98–101
7. Mautner V-F, Nguyen R, Kutta H et al (2010) Bevacizumab induces regression of vestibular schwannomas in patients with neurofibromatosis type 2. Neuro-Oncol 12(1):14–18
8. Plotkin SR, Merker VL, Halpin C et al (2012) Bevacizumab for progressive vestibular schwannoma in neurofibromatosis type 2: a retrospective review of 31 patients. Otol Neurotol 33(6):1046–1052
9. Harris GJ, Plotkin SR, Maccollin M et al (2008) Three-dimensional volumetrics for tracking vestibular schwannoma growth in neurofibromatosis type II. Neurosurgery 62(6):1314–1320
10. Plotkin SR, Halpin C, Blakeley JO et al (2009) Suggested response criteria for phase II antitumor drug studies for neurofibromatosis type 2 related vestibular schwannoma. J Neurooncol 93(1):61–77
11. Committee on Hearing and Equilibrium guidelines for the evaluation of hearing preservation in acoustic neuroma (vestibular schwannoma). American Academy of Otolaryngology-Head and Neck Surgery Foundation, INC. Otolaryngol–Head Neck Surg Off J Am Acad Otolaryngol-Head Neck Surg. sept 1995;113(3):179-180
12. Slattery WH, Fisher LM, Iqbal Z et al (2004) Vestibular schwannoma growth rates in neurofibromatosis type 2 natural history consortium subjects. Otol Neurotol 25(5):811–817
13. Blakeley JO, Evans DG, Adler J et al (2012) Consensus recommendations for current treatments and accelerating clinical trials for patients with neurofibromatosis type 2. Am J Med Genet A 158A(1):24–41
14. Shord SS, Bressler LR, Tierney LA et al (2009) Understanding and managing the possible adverse effects associated with bevacizumab. Am J Health-Syst Pharm 66(11):999–1013
15. Slusarz KM, Merker VL, Muzikansky A et al (2014) Long-term toxicity of bevacizumab therapy in neurofibromatosis 2 patients. Cancer Chemother Pharmacol 73(6):1197–1204
16. Plotkin SR, Halpin C, McKenna MJ et al (2010) Erlotinib for progressive vestibular schwannoma in neurofibromatosis 2 patients. Otol Neurotol 31(7):1135–1143
17. Karajannis MA, Legault G, Hagiwara M et al (2012) Phase II trial of lapatinib in adult and pediatric patients with neurofibromatosis type 2 and progressive vestibular schwannomas. Neuro-Oncol 14(9):1163–1170
18. Ammoun S, Schmid MC, Triner J et al (2011) Nilotinib alone or in combination with selumetinib is a drug candidate for neurofibromatosis type 2. Neuro-Oncol 13(7):759–766
19. Bush ML, Oblinger J, Brendel V et al (2011) AR42, a novel histone deacetylase inhibitor, as a potential therapy for vestibular schwannomas and meningiomas. Neuro-Oncol 13(9):983–999
20. Jacob A, Oblinger J, Bush ML et al (2012) Preclinical validation of AR42, a novel histone deacetylase inhibitor, as treatment for vestibular schwannomas. The Laryngoscope 122(1):174–189
21. Giovannini M, Bonne N-X, Vitte J et al (2014) mTORC1 inhibition delays growth of neurofibromatosis type 2 schwannoma. Neuro-Oncol 16(4):493–504
22. Karajannis MA, Legault G, Hagiwara M et al (2014) Phase II study of everolimus in children and adults with neurofibromatosis type 2 and progressive vestibular schwannomas. Neuro-Oncol 16(2):292–297
23. Subbiah V, Slopis J, Hong DS et al (2012) Treatment of patients with advanced neurofibromatosis type 2 with novel molecularly targeted therapies: from bench to bedside. J Clin Oncol 30(5):e64–e68